ALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Consensus Rating of “Buy” by Brokerages

Shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO) have been given an average recommendation of “Buy” by the seven research firms that are currently covering the firm, MarketBeat.com reports. Seven analysts have rated the stock with a buy rating. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $20.42.

Several equities analysts have commented on ALXO shares. Piper Sandler upped their price target on ALX Oncology from $8.00 to $11.00 and gave the company an “overweight” rating in a report on Wednesday, October 11th. UBS Group dropped their target price on ALX Oncology from $29.00 to $27.00 and set a “buy” rating for the company in a report on Wednesday, October 4th. Stifel Nicolaus dropped their target price on ALX Oncology from $11.00 to $10.00 and set a “buy” rating for the company in a report on Tuesday, November 14th. Cantor Fitzgerald increased their target price on ALX Oncology from $18.00 to $23.00 and gave the stock an “overweight” rating in a report on Wednesday, October 4th. Finally, HC Wainwright increased their target price on ALX Oncology from $16.00 to $17.50 and gave the stock a “buy” rating in a report on Tuesday, October 3rd.

Institutional Trading of ALX Oncology

Several hedge funds and other institutional investors have recently modified their holdings of ALXO. Royal Bank of Canada grew its holdings in shares of ALX Oncology by 226.6% in the 2nd quarter. Royal Bank of Canada now owns 4,001 shares of the company’s stock valued at $30,000 after acquiring an additional 2,776 shares in the last quarter. Legal & General Group Plc grew its holdings in ALX Oncology by 40.6% during the second quarter. Legal & General Group Plc now owns 5,309 shares of the company’s stock worth $43,000 after purchasing an additional 1,534 shares during the period. UBS Group AG grew its holdings in ALX Oncology by 38.7% during the first quarter. UBS Group AG now owns 10,043 shares of the company’s stock worth $45,000 after purchasing an additional 2,801 shares during the period. SG Americas Securities LLC bought a new stake in shares of ALX Oncology during the third quarter worth approximately $48,000. Finally, Citigroup Inc. boosted its holdings in shares of ALX Oncology by 671.8% during the second quarter. Citigroup Inc. now owns 7,139 shares of the company’s stock worth $54,000 after acquiring an additional 6,214 shares during the period. Institutional investors and hedge funds own 83.37% of the company’s stock.

ALX Oncology Price Performance

NASDAQ ALXO opened at $9.50 on Friday. The stock has a 50-day simple moving average of $7.04 and a 200 day simple moving average of $6.62. The company has a debt-to-equity ratio of 0.06, a quick ratio of 12.49 and a current ratio of 5.66. The stock has a market capitalization of $473.29 million, a PE ratio of -2.66 and a beta of 1.41. ALX Oncology has a twelve month low of $3.94 and a twelve month high of $12.33.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. Its lead product candidate is evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents for treatment of various oncology indications, including myelodysplastic syndromes, acute myeloid leukemia, head and neck squamous cell carcinoma, gastric/gastroesophageal junction, and breast cancer.